Causes
- CAR-T cell therapy: the most common cause in blood cancer treatment, usually starting within days of infusion.
- Bispecific T-cell engagers such as blinatumomab
- Some monoclonal antibodies: in the 2006 TGN1412 trial six healthy volunteers developed severe CRS.
- Infections such as severe COVID-19 and stem cell transplantation can cause similar hyperinflammation.
Mechanism
T cells recognizing their target release IFN-γ and other mediators, which activate macrophages and endothelial cells to release large amounts of IL-6 and IL-1. Vascular leak causes hypotension, edema and organ dysfunction. CRS is one form of the broader "cytokine storm".
Symptoms and grading
Fever (≥38°C) is required; the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grades CRS 1-4 by hypotension and hypoxia, from fever alone (grade 1) to needing multiple vasopressors or positive-pressure ventilation (grade 4). Neurotoxicity (ICANS) is graded separately.
Treatment
- Mild: antipyretics, fluids, supportive care
- Moderate or worse: the IL-6 receptor blocker tocilizumab (FDA-approved for CAR-T-related CRS in 2017), corticosteroids if needed
- Severe: intensive care, vasopressors, oxygen support
This is general information; diagnosis and treatment should follow the care team's judgment.
References
- Lee, D. W., Santomasso, B. D., Locke, F. L., et al. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625-638.
- Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., et al. (2018). Cytokine release syndrome. Journal for ImmunoTherapy of Cancer, 6, 56.
- Suntharalingam, G., Perry, M. R., Ward, S., et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine, 355(10), 1018-1028.
- Le, R. Q., Li, L., Yuan, W., et al. (2018). FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist, 23(8), 943-947.